THE ULTIMATE GUIDE TO BOSENTAN

6 The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV in the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) together with bosentan, sitaxentan and ambrisentan are oral therapies accredited for use in PAH. As no oral agent has shown superiority there stays debate regarding which must be util